• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

3.350 -0.040 (-1.18%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about AbCellera Biologics Inc. - Common Shares

< Previous 1 2 3 4 5 Next >
News headline image
AbCellera Reports Full Year 2025 Business Results
February 24, 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Present at Upcoming Investor Conferences in March and April 2026
February 11, 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026
January 22, 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause
January 12, 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera and Bruker Reach Global Settlement of Patent Litigation
December 18, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
December 08, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Appoints Dr. Stephen Quake to its Board of Directors
November 10, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Reports Q3 2025 Business Results
November 06, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Participate at Upcoming Investor Conferences in November and December 2025
October 07, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025
September 29, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer
September 10, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575
August 27, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Participate at Upcoming Investor Conferences in September
August 12, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms
August 07, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025
July 07, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575
May 30, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause
May 14, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit
May 12, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting
May 09, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Reports Q1 2025 Business Results
May 08, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025
April 29, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Participate at Upcoming Investor Conferences in May and June
April 08, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025
April 03, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025
March 25, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Reports Full Year 2024 Business Results
February 27, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Participate at Upcoming Investor Conferences in March
February 11, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Report Full Year 2024 Financial Results on February 27, 2025
January 21, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology
January 13, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Present at Upcoming Investor Conferences in December and January
November 21, 2024
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024
November 07, 2024
From AbCellera Biologics Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap